Louis Breton is chief executive officer and a co-founder of Rampart Bioscience. Mr. Breton has more than 25 years of biotechnology leadership, most recently serving as CEO of Calimmune, a gene therapy company he launched in 2006 with Nobel Laureate David Baltimore, Ph.D., to address chronic and currently incurable diseases including HIV and sickle cell anemia. (Calimmune and its proprietary stem cell gene therapy platform were acquired in 2017 by CSL Behring.) Over the course of his career, Mr. Breton has built three life science companies and contributed to more than 20 product launches, as well as numerous licensing deals and regulatory negotiations. Named as one of the top 100 most inspirational and extraordinary leaders in the life sciences industry by PharmaVOICE magazine, Mr. Breton is a current or former board member of more than a dozen biotech and high-tech companies and is actively involved in numerous charitable projects. He holds a B.S. in Molecular and Cellular Biology from University of Arizona.